Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Q2 2025 Revenue Jumps 154% on Strong Demand for Motion and Fast Motion Shafts
Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company delivering physics-based performance innovations, reported Q2…
-
QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology…
-
Scalability of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Tailings Model Represents Profitable Mining Approach Throughout The Americas
Sustainable mining company ESGold is stretching beyond its nascent Quebec mine tailings cleanup operation to…